$9.09
0.16% today
Nasdaq, Sep 03, 08:46 pm CET
ISIN
US4884451075
Symbol
ZVRA

KemPharm, Inc. Stock price

$9.10
-2.15 19.11% 1M
+1.77 24.15% 6M
+0.76 9.11% YTD
+1.45 18.95% 1Y
+3.49 62.21% 3Y
-0.81 8.19% 5Y
-311.70 97.16% 10Y
-170.10 94.92% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.03 0.33%
ISIN
US4884451075
Symbol
ZVRA
Industry

Key metrics

Basic
Market capitalization
$528.2m
Enterprise Value
$386.3m
Net debt
positive
Cash
$202.6m
Shares outstanding
55.1m
Valuation (TTM | estimate)
P/E
227.5 | 13.2
P/S
8.5 | 5.2
EV/Sales
6.2 | 3.8
EV/FCF
negative
P/B
4.5
Financial Health
Equity Ratio
22.3%
Return on Equity
-266.0%
ROCE
-26.6%
ROIC
-29.4%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$62.0m | $101.4m
EBITDA
$-53.9m | $-10.4m
EBIT
$-60.4m | $-15.7m
Net Income
$2.6m | $38.1m
Free Cash Flow
$-52.5m
Growth (TTM | estimate)
Revenue
158.5% | 329.6%
EBITDA
23.4% | 87.1%
EBIT
18.7% | 82.0%
Net Income
104.0% | 136.1%
Free Cash Flow
6.7%
Margin (TTM | estimate)
Gross
89.7%
EBITDA
-86.8% | -10.3%
EBIT
-97.4%
Net
4.3% | 37.6%
Free Cash Flow
-84.7%
More
EPS
$0.0
FCF per Share
$-1.0
Short interest
11.4%
Employees
59
Rev per Employee
$400.0k
Show more

Is KemPharm, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

KemPharm, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

Buy
93%
Hold
7%

Financial data from KemPharm, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
62 62
159% 159%
100%
- Direct Costs 6.39 6.39
65% 65%
10%
56 56
223% 223%
90%
- Selling and Administrative Expenses 73 73
69% 69%
117%
- Research and Development Expense 26 26
44% 44%
42%
-54 -54
23% 23%
-87%
- Depreciation and Amortization 6.57 6.57
65% 65%
11%
EBIT (Operating Income) EBIT -60 -60
19% 19%
-97%
Net Profit 2.64 2.64
104% 104%
4%

In millions USD.

Don't miss a Thing! We will send you all news about KemPharm, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KemPharm, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 2-...
Neutral
GlobeNewsWire
8 days ago
CELEBRATION, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate in the following September events:
Negative
Investors Business Daily
21 days ago
Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.
More KemPharm, Inc. News

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Head office United States
CEO Neil McFarlane
Employees 59
Founded 2006
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today